Skip to main content
Retour
Watch Compare

Evommune, Inc.

Qualité des données : 100%
EVMN
NYSE Manufacturing Chemicals
25,51 €
▼ 3,14 € (-10,96%)
Cap. Boursière: 1,02 B
Prix
28,30 €
Cap. Boursière
1,02 B
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -76,68 M
Capital efficient — spends only 1,81% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-33,50%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC-30,93%
Net Margin-529,77%
Op. Margin-623,62%

Sécurité

Debt / Equity
N/A
Current Ratio7,87
Interest CoverageN/A

Valorisation

PE (TTM)
-14,80
En dessous de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -14,8 -1,5
P/B — 1,6
ROE % -33,5 -53,5
Net Margin % -529,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

7 analystes
Buy
Actuel
25,51 €
+99.9%
Objectif
51,00 €
48,00 €
50,00 €
55,00 €
Prévisions
P/E Prévisionnel -7,60
BPA Prévisionnel -3,36 €
CA Est. 878 860,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -3,36 €
-4,16 € – -2,60 €
 878 860,0 7
FY2026 -3,21 €
-6,22 € – -2,25 €
 6,11 M 8

Surprises de Résultats

Derniers 2 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,84 € -1,43 € -69,8%
Q32025 -11,36 € -8,07 € +28,9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 13,00 M Net Income (TTM) -68,87 M
ROE -33,50% ROA -30,62%
Gross Margin N/A Operating Margin -623,62%
Net Margin -529,77% Free Cash Flow (TTM) -76,68 M
ROIC -30,93% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,87
Interest Coverage N/A Asset Turnover 0,06
Working Capital 71,53 M Tangible Book Value -183,14 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -14,80 Forward P/E N/A
P/B Ratio N/A P/S Ratio 78,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,52%
Market Cap 1,02 B Enterprise Value 992,51 M
Per Share
EPS (Diluted TTM) -11,22 Revenue / Share 0,36
FCF / Share -2,13 OCF / Share -2,12
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,81% FCF Conversion 111,33%
SBC-Adj. FCF -82,53 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue 13,00 M
Net Income -68,87 M
EPS (Diluted) -11,22
Gross Profit —
Operating Income -81,07 M
EBITDA —
R&D Expenses 74,04 M
SG&A Expenses —
D&A 600 000,0
Interest Expense —
Income Tax 0,0

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 224,95 M
Total Liabilities 19,38 M
Shareholders' Equity 205,57 M
Total Debt —
Cash & Equivalents 44,06 M
Current Assets 153,48 M
Current Liabilities 17,91 M